

Apoptotic Therapeutics in Oncology - Where to Commercialize?

Published: 2009-NOV-30

Pages: 803

Format: PDF

Price: 3400 USD (Single User License)

Description

This report comprises defined and up to date development strategies for 171 apoptotic drugs (519 projects) within the portfolio of 125 investigators, from Ceased to Pre-registration. The report extensively analyses 146 identified targets of apoptotic drugs, organized into 120 drug target profiles, and assesses them in 53 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by:

Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any apoptotic drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

Table of Contents

1	Executive Summary	3
2	About Cancer Highlights	4
3	Methodologies	6
4	Table of Contents	8
4.1	List of Figures	18
4.2	List of Tables	18
5	Introduction	27
5.1	The Scope of this Report	27
5.2	Definitions	31
5.3	Abbreviations	31
6	Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment	32
6.1	Drug Repositioning in Oncology	32
6.2	Introduction to Apoptotic Therapeutic Targets in Oncology	33
6.2.1	Auxiliary Transport Protein Activity Targets	36
6.2.2	Carboxy-lyase Activity Targets	37
6.2.3	Caspase Activator Activity Targets	38
6.2.4	Catalytic Activity Targets	39
6.2.5	Cell Adhesion Molecule Activity Targets	46
6.2.6	Cell Adhesion Molecule Activity Targets	47
6.2.7	Chaperone Activity Targets	50
6.2.8	Complement Activity Targets	54
6.2.9	Cysteine-type Peptidase Activity Targets	56
6.2.10	Cytokine Activity Targets	61
6.2.11	DNA Binding Targets	64
6.2.12	DNA topoisomerase Activity Targets	65

BioMarket Group - A Global Online Aggregator of Life Science Market Research

6.2.13	G-protein Coupled Receptor Activity Targets	68
6.2.14	Glutathione Transferase Activity Targets	72
6.2.15	Growth Factor Activity Targets	73
6.2.16	Growth Factor Binding Targets	74
6.2.17	GTPase Activity Targets	75
6.2.18	Hydrolase Activity Targets	82
6.2.19	Kinase Activity Targets	83
6.2.20	Kinase Regulator Activity Targets	91
6.2.21	Ligand-dependent Nuclear Receptor Activity Targets	93
6.2.22	Ligase Activity Targets	95
6.2.23	Lipid Kinase Activity Targets	99
6.2.24	Metallopeptidase Activity Targets	103
6.2.25	Molecular Function Unknown Targets	104
6.2.26	Motor Activity Targets	107
6.2.27	Oxidoreductase Activity Targets	108
6.2.28	Peptide Hormone Targets	110
6.2.29	Phosphoric Diester Hydrolase Activity Targets	111
6.2.30	Protein Binding Targets	113
6.2.31	Protein Serine/Threonine Kinase Activity Targets	115
6.2.32	Protein-Tyrosine Kinase Activity Targets	134
6.2.33	Receptor Activity Targets	136
6.2.34	Receptor Signaling Complex Scaffold Activity Targets	153
6.2.35	Receptor Signaling Protein Serine/Threonine Kinase Activity Targets	158
6.2.36	RNA Binding Targets	159
6.2.37	Serine-type Peptidase Activity Targets	160
6.2.38	Structural Constituent of Cytoskeleton Targets	161
6.2.39	Superoxide Dismutase Activity Targets	162
6.2.40	T cell Receptor Activity Targets	164
6.2.41	Transcription Factor Activity Targets	165
6.2.42	Transcription Regulator Activity Targets	173
6.2.43	Transferase Activity Targets	184
6.2.44	Translation Regulator Activity Targets	185
6.2.45	Transmembrane Receptor Activity Targets	187
6.2.46	Transmembrane Receptor Protein Tyrosine Kinase Activity Targets	191
6.2.47	Transporter Activity Targets	206
6.2.48	Ubiquitin-specific Protease Activity Targets	211
6.2.49	Other Drug Targets	213
6.3	The Cancer Genome Project and Apoptotic Therapeutic Targets in Oncology	215
6.3.1	Apoptotic Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer	215
6.4	Structure-based Drug Design in Apoptotic Therapeutics is Stimulated by Available Structure Data on Biological Targets	218
6.5	Target-Target Interactions among Identified Apoptotic Therapeutics Targets in Oncology	222
6.6	The Drug-Target Interactome	227
6.7	Protein Expression Levels of Identified Apoptotic Therapeutic Targets in Oncology	232
6.8	Pathway Analysis of Cancer Apoptotic Therapeutic Targets	236
7	The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline?	277
7.1	Terminated Drug Target Profiles of Cancer Apoptotic Drugs	287
7.2	Pre-Registration: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology	289
7.3	Phase III Clinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology	290
7.4	Phase II Clinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology	291
7.5	Phase I Clinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology	294
7.6	Preclinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology	298
7.7	Development Profiles of All Apoptotic Drugs in Oncology	301
8	Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type	312
8.1	Small Molecules	314
8.1.1	Background	314
8.1.2	Target Profiles of Small Molecular Drugs	315
8.2	Peptide/Protein Drugs	329
8.2.1	Background	329
8.2.2	Target Profiles of Peptide and Protein Drugs	330
8.3	Antibodies and Antibody-like Structures	334
8.3.1	Background	334
8.3.2	Target Profiles of Antibody Drugs	334
8.4	Nucleic Acid Therapies	337
8.4.1	Background	337
8.4.2	Target Profiles of Nucleic Acid Drugs	338
8.5	Gene Therapy	341
8.5.1	Background	341
8.5.2	Target Profiles of Gene Therapy Drugs	341
8.6	Drug Delivery and Nanotechnology	344
8.6.1	Background	344
8.6.2	Target Profiles of Reformulated Drugs	344
8.7	The Competition Through Close Mechanistic Approximation of Apoptotic Cancer Therapeutics	345
8.8	Compound Strategies based on Sub-Cellular Localization of Apoptotic Drug Targets in Oncology	349
9	Selecting Cancer Indications for Apoptotic Therapeutics	356
9.1	Acute Lymphocytic Leukemia	358

BioMarket Group - A Global Online Aggregator of Life Science Market Research

9.2	Acute Myelogenous Leukemia	359	
9.3	Adrenal Cancer	361	
9.4	B-cell Lymphoma	362	
9.5	Basal Cell Cancer	364	
9.6	Biliary Cancer	365	
9.7	Bladder Cancer	366	
9.8	Bone Cancer	367	
9.9	Brain Cancer	368	
9.10	Breast Cancer	370	
9.11	Carcinoid	373	
9.12	Cervical Cancer	374	
9.13	Chronic Lymphocytic Leukemia	375	
9.14	Chronic Myelogenous Leukemia	377	
9.15	Colorectal Cancer	379	
9.16	Endometrial Cancer	382	
9.17	Ewing's Sarcoma	383	
9.18	Fallopian Tube Cancer	384	
9.19	Fibro Sarcoma	385	
9.20	Gastrointestinal Cancer (general)	386	
9.21	Gastrointestinal Stomach Cancer	387	
9.22	Gastrointestinal Stromal Cancer	389	
9.23	Head and Neck Cancer	390	
9.24	Hodgkin's Lymphoma	392	
9.25	Leiomyo Sarcoma	393	
9.26	Leukemia (general)	394	
9.27	Lipo Sarcoma	395	
9.28	Liver Cancer	396	
9.29	Lung Cancer (general)	397	
9.30	Lymphoma (general)	398	
9.31	Melanoma	400	
9.32	Mesothelioma	402	
9.33	Myelodysplastic Syndrome	403	
9.34	Myeloma	405	
9.35	Nasopharyngeal Cancer	407	
9.36	non-Hodgkin's Lymphoma	408	
9.37	Non-Small Cell Lung Cancer	410	
9.38	Oesophageal Cancer	413	
9.39	Osteo Sarcoma	414	
9.40	Ovarian Cancer	415	
9.41	Pancreatic Cancer	418	
9.42	Peritoneal Cancer	420	
9.43	Prostate Cancer	421	
9.44	Renal Cancer	424	
9.45	Sarcoma (general)	426	
9.46	Small Cell Lung Cancer	428	
9.47	Soft Tissue Sarcoma	430	
9.48	Squamous Cell Cancer	431	
9.49	T-cell Lymphoma	432	
9.50	Testicular Cancer	433	
9.51	Thymoma Cancer	434	
9.52	Thyroid Cancer	435	
9.53	Unspecified Cancer Indication	436	
10	Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator		441
10.1	Abbott	445	
10.2	AbGenomics	449	
10.3	Access	451	
10.4	Advanced Life Sciences	453	
10.5	AEgera	455	
10.6	Aeterna Zentaris	459	
10.7	Aida Pharmaceuticals	463	
10.8	Ambrilia Biopharma	466	
10.9	Amgen	468	
10.10	Anadys Pharmaceuticals	472	
10.11	Anavex Life Sciences	474	
10.12	Antisoma	477	
10.13	Aphios	480	
10.14	Apogenix	482	
10.15	ApopLogic Pharmaceuticals	485	
10.16	Arno Therapeutics	489	
10.17	ArQule	491	
10.18	Ascenta Therapeutics	495	
10.19	Attenuon	498	
10.20	Basilea Pharmaceutica	501	
10.21	Bayer	504	
10.22	BioAxone	508	
10.23	Biogen Idec	510	

BioMarket Group - A Global Online Aggregator of Life Science Market Research

10.24	BioInvent	512	
10.25	BioLineRx	514	
10.26	Bionovo	516	
10.27	BioVex	518	
10.28	Cancer Research Technology	520	
10.29	Cephalon	522	
10.30	ChemoCentryx	525	
10.31	Chlorogen	527	
10.32	Chroma Therapeutics	529	
10.33	Cleveland BioLabs	531	
10.34	CombinatoRx	533	
10.35	Coronado Biosciences	535	
10.36	Critical Outcome Technologies	538	
10.37	Curis	540	
10.38	Cyclacel	542	
10.39	Cylene Pharmaceuticals	546	
10.40	Cytochroma	549	
10.41	Daewoong	551	
10.42	Daiichi Sankyo	553	
10.43	Dainippon Sumitomo Pharma	556	
10.44	Eisai	559	
10.45	Eleos	562	
10.46	Eli Lilly	565	
10.47	EntreMed	568	
10.48	Enzon	571	
10.49	EpiCept	574	
10.50	Exelixis	579	
10.51	Genentech	582	
10.52	Genta	586	
10.53	Genzyme	590	
10.54	Gerolymatos	592	
10.55	Geron	594	
10.56	GlycoGenesys	597	
10.57	GPC Biotech	600	
10.58	Hoffmann-La Roche	602	
10.59	Hollis-Eden Pharmaceuticals	606	
10.60	Human Genome Sciences	608	
10.61	Idera Pharmaceuticals	613	
10.62	Infinity Pharmaceuticals	615	
10.63	InNexus Biotechnology	618	
10.64	Insmed	620	
10.65	Intradigm	622	
10.66	Introgen Therapeutics	624	
10.67	Isis Pharmaceuticals	628	
10.68	ISU ABXIS	631	
10.69	Johnson & Johnson	633	
10.70	Kalypsys	636	
10.71	Keryx Biopharmaceuticals	639	
10.72	Kyowa Hakko Kirin	642	
10.73	Lorus Therapeutics	645	
10.74	Medisyn Technologies	647	
10.75	Merck & Co	650	
10.76	MethylGene	652	
10.77	NeoPharm	655	
10.78	NIH – The US National Institute of Health	657	
10.79	Nippon Shinyaku	659	
10.80	Non-industrial Sources	661	
10.81	Novacea	663	
10.82	Novartis	666	
10.83	Novelix	673	
10.84	Novogen	675	
10.85	Onconova	679	
10.86	OSI Pharmaceuticals	681	
10.87	OXiGENE	684	
10.88	PanaGin	688	
10.89	Patrys	691	
10.90	Pfizer	693	
10.91	Pharmacyclics	695	
10.92	PharmaMar	700	
10.93	Pharminox	704	
10.94	Phytomedics	706	
10.95	Pierre Fabre	708	
10.96	QLT	710	
10.97	Reata Pharmaceuticals	713	
10.98	Regulon	716	
10.99	Rosetta Genomics	719	

BioMarket Group - A Global Online Aggregator of Life Science Market Research

10.100	Sanofi-Aventis	721
10.101	Santaris Pharma	724
10.102	Semafore Pharmaceuticals	726
10.103	Senesco Technologies	729
10.104	Sigma-Tau	731
10.105	SRI International	733
10.106	SuperGen	736
10.107	Switch Pharma	740
10.108	Symbiotec	742
10.109	Taxolog	744
10.110	Telik	747
10.111	Thallion Pharmaceuticals	750
10.112	Tigris Pharmaceuticals	753
10.113	TopoTarget	755
10.114	Tracon Pharmaceuticals	760
10.115	Trubion	763
10.116	UMN Pharma	765
10.117	ValiRx	767
10.118	Vascular Biogenics	770
10.119	Vertex Pharmaceuticals	772
10.120	VioQuest	775
10.121	Viragen	778
10.122	Viralytics	781
10.123	ViroTarg	784
10.124	VM Discovery	787
10.125	ZymoGenetics	790
11	Disclaimer	793
12	Drug Index	794
13	Company Index	799

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Apoptotic Drug Targets in Oncology	226
Figure 2: The Drug-Protein Interactome of Apoptotic Drugs –Large Clusters	229
Figure 3: The Drug-Protein Interactome of Apoptotic Drugs – Small Clusters	230
Figure 4: Head-to-Head Targeting Interactome of Apoptotic Drugs	231
Figure 5: Distribution of Compound Types among Apoptotic Drugs in Oncology	349
Figure 6: Primary Sub-cellular Localization of Drug Targets	350

4.2 List of Tables

Table 1: Head to Head Competition among Apoptotic Drugs in Oncology	27
Table 2: Overall Breakdown of the Included Apoptotic Pipeline by Cancer Indication and Stage of Development	27
Table 3: Overview of Drug Target Profile Themes	33
Table 4: Terminally Ceased Therapeutic Apoptotic Targets in Oncology	34
Table 5: Drug Targets of Apoptotic Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census	216
Table 6: Identity of Apoptotic Drug Targets with Available Biological Structures	219
Table 7: Number of Target-Target Interactions among Apoptotic Drug Targets in Oncology	222
Table 8: Drug-Protein Interactome Clusters of Apoptotic Drugs in Oncology	227
Table 9: Apoptotic Drug Targets with Available Protein Expression Profiles	232
Table 10: Pathway Summary	236
Table 11: Drug Targets without any Identified Assigned Pathways	236
Table 12: Pathway Profiles According to BioCarta of Apoptotic Drug Targets in Oncology	238
Table 13: Pathway Profiles According to KEGG of Apoptotic Drug Targets in Oncology	256
Table 14: Pathway Profiles According to NetPath of Apoptotic Drug Targets in Oncology	273
Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness	285
Table 16: Top Competitive Apoptotic Target Profiles in Oncology	285
Table 17: Terminated Drug Target Strategies of Apoptotic Drugs in Oncology	287
Table 18: New and Unique Apoptotic Target Strategies in Cancer Currently in Pre-Registration	289
Table 19: New and Unique Apoptotic Target Strategies in Cancer Currently in Phase III Clinical Development	290
Table 20: New and Unique Apoptotic Target Strategies in Cancer Currently in Phase II Clinical Development	291
Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Apoptotic Drugs in Oncology	293
Table 22: New and Unique Apoptotic Target Strategies in Cancer Currently in Phase I Clinical Development	294
Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Apoptotic Drugs in Oncology	296
Table 24: New and Unique Apoptotic Target Strategies in Oncology Currently in Preclinical Development	298
Table 25: The Competition Through Close Mechanistic Approximation Between Preclinical Apoptotic Drugs in Oncology	300
Table 26: The Progression, Maturity and Competitive Comparison of Apoptotic Drug Target Profiles in Cancer Drug Development	301
Table 27: Overview of Compound Strategy Competition Among Apoptotic Drugs in Oncology	313
Table 28: Overview of the Competitive Landscape of Apoptotic Small Molecular Drugs in Oncology	315
Table 29: The Competition Through Close Mechanistic Approximation between Apoptotic Small Molecule Drugs in Oncology	316
Table 30: Competitive Comparison of Target Profiles of Apoptotic Small Molecule Drugs in Oncology	318
Table 31: Overview of the Competitive Landscape of Peptide Based Apoptotic Drugs in Oncology	330
Table 32: The Competition Through Close Mechanistic Approximation between Apoptotic Peptide Based Drugs in Oncology	330
Table 33: Competitive Comparison of Target Profiles of Apoptotic Peptide Based Drugs in Oncology	331
Table 34: Overview of the Competitive Landscape of Apoptotic Protein Based Drugs in Oncology	332
Table 35: The Competition Through Close Mechanistic Approximation between Apoptotic Protein Based Drugs in Oncology	332
Table 36: Competitive Comparison of Apoptotic Protein Based Drugs in Oncology	333

BioMarket Group - A Global Online Aggregator of Life Science Market Research

Table 37: Overview of the Competitive Landscape of Apoptotic Antibody Drugs in Oncology	334
Table 38: The Competition Through Close Mechanistic Approximation between Apoptotic Antibody Drugs in Oncology	335
Table 39: Competitive Comparison of Target Profiles of Apoptotic Antibody Drugs in Oncology	335
Table 40: Overview of the Competitive Landscape of Apoptotic Nucleic Acid Therapy Drugs in Oncology	338
Table 41: The Competition Through Close Mechanistic Approximation between Apoptotic Nucleic Acid Therapy Drugs in Oncology	338
Table 42: Competitive Comparison of Target Profiles of Apoptotic Nucleic Acid Drugs in Oncology	339
Table 43: Vectors in Gene Therapy	341
Table 44: Overview of the Competitive Landscape of Apoptotic Gene Therapy Drugs in Oncology	341
Table 45: The Competition Through Close Mechanistic Approximation between Apoptotic Gene Therapy Drugs in Oncology	342
Table 46: Competitive Comparison of Target Profiles of Apoptotic Gene Therapy Based Drugs in Oncology	342
Table 47: Overview of the Competitive Landscape of Reformulated Apoptotic Drugs in Oncology	344
Table 48: Competitive Comparison of Target Profiles of Reformulated Apoptotic Drugs in Oncology	344
Table 49: The Competition Through Close Mechanistic Approximation Among All Apoptotic Drugs in Oncology	345
Table 50: Compound Strategies based on Sub-Cellular Localization of Apoptotic Drug Targets in Oncology	350
Table 51: Competitive Summary of Apoptotic Drugs by Cancer Indication	356
Table 52: Drug Target Profiles of Apoptotic Drugs for the Treatment of Acute Lymphocytic Leukemia	358
Table 53: Drug Target Profiles of Apoptotic Drugs for the Treatment of Acute Myelogenous Leukemia	359
Table 54: The Competition through Close Mechanistic Approximation between Acute Myelogenous Drugs	360
Table 55: Drug Target Profiles of Apoptotic Drugs for the Treatment of Adrenal Cancer	361
Table 56: Drug Target Profiles of Apoptotic Drugs for the Treatment of B-cell Lymphoma	362
Table 57: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs	363
Table 58: Drug Target Profiles of Apoptotic Drugs for the Treatment of Basal Cell Cancer	364
Table 59: Drug Target Profiles of Apoptotic Drugs for the Treatment of Biliary Cancer	365
Table 60: Drug Target Profiles of Apoptotic Drugs for the Treatment of Bladder Cancer	366
Table 61: Drug Target Profiles of Apoptotic Drugs for the Treatment of Bone Cancer	367
Table 62: Drug Target Profiles of Apoptotic Drugs for the Treatment of Brain Cancer	368
Table 63: Drug Target Profiles of Apoptotic Drugs for the Treatment of Breast Cancer	370
Table 64: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs	372
Table 65: Drug Target Profiles of Apoptotic Drugs for the Treatment of Carcinoid	373
Table 66: Drug Target Profiles of Apoptotic Drugs for the Treatment of Cervical Cancer	374
Table 67: Drug Target Profiles of Apoptotic Drugs for the Treatment of Chronic Lymphocytic Leukemia	375
Table 68: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs	376
Table 69: Drug Target Profiles of Apoptotic Drugs for the Treatment of Chronic Myelogenous Leukemia	377
Table 70: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs	378
Table 71: Drug Target Profiles of Apoptotic Drugs for the Treatment of Colorectal Cancer	379
Table 72: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs	380
Table 73: Drug Target Profiles of Apoptotic Drugs for the Treatment of Endometrial Cancer	382
Table 74: Drug Target Profiles of Apoptotic Drugs for the Treatment of Ewing's Sarcoma	383
Table 75: Drug Target Profiles of Apoptotic Drugs for the Treatment of Fallopian Tube Cancer	384
Table 76: Drug Target Profiles of Apoptotic Drugs for the Treatment of Fibro Sarcoma	385
Table 77: Drug Target Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Cancer (general)	386
Table 78: Drug Target Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Stomach Cancer	387
Table 79: Drug Target Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Stromal Cancer	389
Table 80: Drug Target Profiles of Apoptotic Drugs for the Treatment of Head and Neck Cancer	390
Table 81: Drug Target Profiles of Apoptotic Drugs for the Treatment of Hodgkin's Lymphoma	392
Table 82: Drug Target Profiles of Apoptotic Drugs for the Treatment of Leiomyo Sarcoma	393
Table 83: Drug Target Profiles of Apoptotic Drugs for the Treatment of Leukemia (general)	394
Table 84: Drug Target Profiles of Apoptotic Drugs for the Treatment of Lipo Sarcoma	395
Table 85: Drug Target Profiles of Apoptotic Drugs for the Treatment of Liver Cancer	396
Table 86: Drug Target Profiles of Apoptotic Drugs for the Treatment of Lung Cancer (general)	397
Table 87: Drug Target Profiles of Apoptotic Drugs for the Treatment of Lymphoma (general)	398
Table 88: Drug Target Profiles of Apoptotic Drugs for the Treatment of Melanoma	400
Table 89: The Competition through Close Mechanistic Approximation between Melanoma Cancer Drugs	401
Table 90: Drug Target Profiles of Apoptotic Drugs for the Treatment of Mesothelioma	402
Table 91: Drug Target Profiles of Apoptotic Drugs for the Treatment of Myelodysplastic Syndrome	403
Table 92: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs	404
Table 93: Drug Target Profiles of Apoptotic Drugs for the Treatment of Myeloma	405
Table 94: The Competition through Close Mechanistic Approximation between Myeloma Drugs	406
Table 95: Drug Target Profiles of Apoptotic Drugs for the Treatment of Nasopharyngeal Cancer	407
Table 96: Drug Target Profiles of Apoptotic Drugs for the Treatment of non-Hodgkin's Lymphoma	408
Table 97: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs	409
Table 98: Drug Target Profiles of Apoptotic Drugs for the Treatment of Non-Small Cell Lung Cancer	410
Table 99: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs	412
Table 100: Drug Target Profiles of Apoptotic Drugs for the Treatment of Oesophageal Cancer	413
Table 101: Drug Target Profiles of Apoptotic Drugs for the Treatment of Osteo Sarcoma	414
Table 102: Drug Target Profiles of Apoptotic Drugs for the Treatment of Ovarian Cancer	415
Table 103: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs	417
Table 104: Drug Target Profiles of Apoptotic Drugs for the Treatment of Pancreatic Cancer	418
Table 105: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs	419
Table 106: Drug Target Profiles of Apoptotic Drugs for the Treatment of Peritoneal Cancer	420
Table 107: Drug Target Profiles of Apoptotic Drugs for the Treatment of Prostate Cancer	421
Table 108: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs	423
Table 109: Drug Target Profiles of Apoptotic Drugs for the Treatment of Renal Cancer	424
Table 110: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs	425
Table 111: Drug Target Profiles of Apoptotic Drugs for the Treatment of Sarcoma (general)	426
Table 112: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs	427

BioMarket Group - A Global Online Aggregator of Life Science Market Research

Table 113: Drug Target Profiles of Apoptotic Drugs for the Treatment of Small Cell Lung Cancer	428	
Table 114: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs	429	
Table 115: Drug Target Profiles of Apoptotic Drugs for the Treatment of Soft Tissue Sarcoma	430	
Table 116: Drug Target Profiles of Apoptotic Drugs for the Treatment of Squamous Cell Cancer	431	
Table 117: Drug Target Profiles of Apoptotic Drugs for the Treatment of T-cell Lymphoma	432	
Table 118: Drug Target Profiles of Apoptotic Drugs for the Treatment of T-cell Lymphoma	432	
Table 119: Drug Target Profiles of Apoptotic Drugs for the Treatment of Testicular Cancer	433	
Table 120: Drug Target Profiles of Apoptotic Drugs for the Treatment of Thymoma Cancer	434	
Table 121: Drug Target Profiles of Apoptotic Drugs for the Treatment of Thyroid Cancer	435	
Table 122: Drug Target Profiles of Apoptotic Drugs for the Treatment of Unspecified Cancer Indication	436	
Table 123: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs	439	
Table 124: Abbott's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	445	
Table 125: AbGenomics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	449	
Table 126: Access' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	451	
Table 127: Advanced Life Sciences' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	453	
Table 128: AEgera's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	455	
Table 129: Aeterna Zentaris' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	459	
Table 130: Aida Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	463	
Table 131: Ambrilia Biopharma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	466	
Table 132: Amgen's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	468	
Table 133: Anadys Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	472	
Table 134: Anavex Life Sciences' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	474	
Table 135: Antisoma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	477	
Table 136: Aphios' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	480	
Table 137: Apogenix's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	482	
Table 138: ApopLogic Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	485	
Table 139: Arno Therapeutics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	489	
Table 140: ArQule's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	491	
Table 141: Ascenta Therapeutics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	495	
Table 142: Attenuon's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	498	
Table 143: Basilea Pharmaceutica's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	501	
Table 144: Bayer's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	504	
Table 145: BioAxone's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	508	
Table 146: Biogen Idec's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	510	
Table 147: BiolInvent's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	512	
Table 148: BioLineRx's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	514	
Table 149: Bionovo's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	516	
Table 150: BioVex's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	518	
Table 151: Cancer Research Technology's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	520	
Table 152: Cephalon's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	522	
Table 153: ChemoCentryx's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	525	
Table 154: Chlorogen's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	527	
Table 155: Chroma Therapeutics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	529	
Table 156: Cleveland Biolabs' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	531	
Table 157: CombinatoRx's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	533	
Table 158: Coronado Biosciences' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	535	
Table 159: Critical Outcome Technologies' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	538	
Table 160: Curis' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	540	
Table 161: Cyclacel's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	542	
Table 162: Cylene Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	546	
Table 163: Cytochroma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	549	
Table 164: Daewoong's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	551	
Table 165: Daiichi Sankyo's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	553	
Table 166: Dainippon Sumitomo Pharma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	556	
Table 167: Eisai's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	559	
Table 168: Eleos' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	562	
Table 169: Eli Lilly's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	565	
Table 170: EntrezMed's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	568	
Table 171: Enzon's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	571	
Table 172: EpiCept's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	574	
Table 173: Exelixis' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	579	
Table 174: Genentech's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	582	
Table 175: Genta's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	586	
Table 176: Genzyme's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	590	
Table 177: Gerolymatos' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	592	
Table 178: Geron's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	594	
Table 179: GlycoGenesys' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	597	
Table 180: GPC Biotech's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	600	
Table 181: Hoffmann-La Roche's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	602	
Table 182: Hollis-Eden Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	606	
Table 183: Human Genome Sciences' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	608	
Table 184: Idera Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	613	
Table 185: Infinity Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	615	
Table 186: InNexus Biotechnology's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	618	
Table 187: Insmed's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	620	
Table 188: Intradigm's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	622	

BioMarket Group - A Global Online Aggregator of Life Science Market Research

Table 189: Introgen Therapeutics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	624
Table 190: Isis Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	628
Table 191: ISU ABXIS' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	631
Table 192: Johnson & Johnson's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	633
Table 193: Kalypsys' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	636
Table 194: Keryx Biopharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	639
Table 195: Kyowa Hakko Kirin's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	642
Table 196: Lorus Therapeutics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	645
Table 197: Medisyn Technologies' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	647
Table 198: Merck & Co's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	650
Table 199: MethylGene's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	652
Table 200: NeoPharm's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	655
Table 201: NIH's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	657
Table 202: Nippon Shinyaku's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	659
Table 203: Non-industrial source's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	661
Table 204: Novacea's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	663
Table 205: Novartis' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	666
Table 206: Novelix's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	673
Table 207: Novogen's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	675
Table 208: Onconova's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	679
Table 209: OSI Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	681
Table 210: OXiGENE's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	684
Table 211: PanaGen's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	688
Table 212: Patrys' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	691
Table 213: Pfizer's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	693
Table 214: Pharmacyclics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	695
Table 215: PharmaMar's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	700
Table 216: Pharminox's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	704
Table 217: Phytomedics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	706
Table 218: Pierre Fabre's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	708
Table 219: QLT's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	710
Table 220: Reata Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	713
Table 221: Regulon's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	716
Table 222: Rosetta Genomics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	719
Table 223: Sanofi-Aventis' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	721
Table 224: Santaris Pharma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	724
Table 225: Semafore Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	726
Table 226: Senesco Technologies' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	729
Table 227: Sigma-Tau's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	731
Table 228: SRI International's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	733
Table 229: SuperGen's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	736
Table 230: Switch Phar's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	740
Table 231: Symbiotec's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	742
Table 232: Taxolog's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	744
Table 233: Telik's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	747
Table 234: Thallion Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	750
Table 235: Tigris Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	753
Table 236: TopoTarget's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	755
Table 237: Tracoon Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	760
Table 238: Trubion's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	763
Table 239: UMN Pharma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	765
Table 240: ValiRx's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	767
Table 241: Vascular Biogenics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	770
Table 242: Vertex Pharmaceuticals' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	772
Table 243: VioQuest's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	775
Table 244: Viragen's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	778
Table 245: Viralytics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	781
Table 246: ViroTarg's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	784
Table 247: VM Discovery's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	787
Table 248: ZymoGenetics' Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out	790

Ordering

Order Online - <http://www.biomarketgroup.com/market-research-report/apoptotic-therapeutics-in-oncology-where-to-commercialize.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit

<http://www.biomarketgroup.com/market-research-report/contacts/>

Order Information

Please verify that the product information is correct:

Product Name: **Apoptotic Therapeutics in Oncology - Where to Commercialize?**

Web Address: <http://www.biomarketgroup.com/market-research-report/apoptotic-therapeutics-in-oncology-where-to-commercialize.html>

Format: PDF

Price: 3400 USD (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD.

Delivery within Sweden is subject to VAT at 25%.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: _____

Name: _____

Email Address:* _____

Job Title: _____

Organization: _____

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number:

Address: _____

Zip Code: _____

City: _____

State: _____

Country: _____

Phone Number: _____

Fax Number: _____

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:**
- American Express
 - Master Card
 - Visa

Cardholder Name: _____

Expiry Date (MM/YY): _____

Card Number: _____

CVV Number: _____

- Pay by check:**

Please post the check, accompanied by this form, to:
BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

- Pay by wire transfer:** Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please supply purchase order number if needed:

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at

<http://www.biomarketgroup.com/market-research-report/biomarket-group-full-terms-and-conditions/>

Please fax this form to: +46-8-56849191